<DOC>
	<DOCNO>NCT00112437</DOCNO>
	<brief_summary>This 2-year study examine effect new experimental medication ( MK0822 ) postmenopausal osteoporosis . This study enroll approximately 375 postmenopausal woman , randomly assign 4 different dos MK0822or placebo . Measurements perform study include : bone mineral density scan , spine x-ray , laboratory blood urine test , height measurement optional bone biopsy ( end 2 year ) .</brief_summary>
	<brief_title>A Study Examine Effects Experimental Drug Postmenopausal Osteoporosis ( MK-0822-004 )</brief_title>
	<detailed_description>Study Extension : Participants complete 24 month base study invite continue three extension : MK0822-004-10 , extend study 36 month , MK0822-004-20 ( NCT00112437 ) extend study 60 month , MK0822-004-30 ( NCT00112437 ) , extend study 120 month . - In first extension , participant re-randomized 50 mg MK0822 placebo OW 12 month . - In second extension , participant initially randomize MK0822 3 mg placebo OW base study receive MK0822 50 mg weekly Years 4 &amp; 5 ; participant remain treatment Year 3 . - In third extension , participant receive odanacatib weekly Years 6-10 . Study arm extension include 50 mg MK0822 placebo first two extension 50 mg MK0822 third extension . Extension Studies : MK0822-004-10 ( NCT00112437 ) Extension : Patient participate complete 24 month treatment base study MK0822-004-20 ( NCT00112437 ) Extension : Patient participate complete 36 month treatment base extension study . MK0822-004-30 ( NCT00112437 ) Extension : Patient participate complete 60 month treatment base extension study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Postmenopausal 5 year , define menses least 5 year OR least 5 year status post bilateral oophorectomy Bone mineral density Tscore hip spine 2.0 less Spinal anatomy suitable dualenergy xray absorptiometry ( DXA ) . At lumbar spine , evidence vertebral fracture least 3 vertebrae L1 L4 region baseline spine film . ( Significant scoliosis , bony trauma , degenerative joint disease , sequelae orthopedic procedure result anatomy unsuitable accurate bone densitometry must absent lumbar spine . ) At least one hip must evaluable DXA ( e.g. , contain hardware orthopedic procedure ) In state general health allow successful completion trial Agreement use medication treat osteoporosis study History prior osteoporotic fracture ( unless decline treatment ineligible osteoporosis therapy ) Past treatment osteoporosis medication , steroid , hormone replacement , well various medication affect bone may exclusionary . ( Different exclusion criterion apply bone active drug . For example , prior use intravenous ( IV ) bisphosphonates permit . By contrast , prior use hormone replacement several year permit occur within past 6 month . Please ask study doctor detail ) Significant clinical laboratory abnormality screen visit study , opinion investigator , could complicate interpretation study result pose additional risk patient ( example , patient nonambulatory exclude reason )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>